carboplatin,durvalumab,paclitaxel,olaparib,bevacizumab
astrazeneca,merck,roche
['duo-o', 'gyn', 'brca', 'cam ']
waiting for the gyn onc oral to begin in hall d1 #asco23, what do you anticipate from duo-o study? control arm inferior to soc for hrd/non-brcam pts. will there be any benefit for hrp patients? waiting for commentary by c. fotopoulou 
Ασυνάρτητος και ημιτελής. Passionate and perfectionist. Med Onc with special love to Gyn Onc and prostate cancer.